UK-based Mundipharma International has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the opioid overdose reversal treatment Nyxoid (intranasal naloxone spray).
Mundipharma’s new formulation of a drug which has been in routine practice to reverse the effects of opioid overdose for more than 40 years, is designed to support take-home naloxone programs and provide those who are first on the scene in overdose situations with an easy to use, needle-free option.
Rachel Gooch, head of addiction therapy at Mundipharma International, said: “We know that in emergency circumstances, rapid administration of a reversal agent is critical to preserving life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze